Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Filings indexed 767 across all filing types
Latest filing 2022-03-23 Earnings Release
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Fourth Quarter and Full Year Financial Results
Earnings Release Classification · 1% confidence The document is a press release from MaxCyte, Inc. announcing its fourth quarter and full-year 2021 financial results. It includes key financial highlights, revenue guidance for 2022, operational updates, and details for an upcoming earnings conference call. This fits the definition of an Earnings Release (ER), as it is the initial announcement of periodic financial results containing key highlights rather than a full 10-K or interim report. FY 2021
2022-03-23 English
10-K
Annual Report FY 2021
2022-03-22 English
8-K
Regulatory Filings
2022-03-22 English
FORM 3 SUBMISSION
Director's Dealing
2022-03-17 English
MaxCyte, Names Cenk Sumen Chief Scientific Officer
Board/Management Information Classification · 1% confidence The document is a press release issued via the London Stock Exchange's RNS (Regulatory News Service) announcing the appointment of a new Chief Scientific Officer (CSO) at MaxCyte, Inc. Since the document details a change in senior management, it falls under the 'Board/Management Information' category.
2022-03-10 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by BlackRock, Inc. regarding their shareholding in MaxCyte, Inc. This is a classic regulatory disclosure document used to notify the market when a shareholder crosses a specific ownership threshold. According to the provided filing definitions, this falls under 'Major Shareholding Notification' (Code: MRQ).
2022-03-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.